ENFUVIRTIDE: 758 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
758
Total FAERS Reports
33 (4.4%)
Deaths Reported
161
Hospitalizations
758
As Primary/Secondary Suspect
20
Life-Threatening
3
Disabilities
Mar 13, 2003
FDA Approved
Discontinued
Status
FDA Application: 021481 ·
First Report: 2001 · Latest Report: 20240208
What Are the Most Common ENFUVIRTIDE Side Effects?
#1 Most Reported
Lipodystrophy acquired
150 reports (19.8%)
#2 Most Reported
Mitochondrial toxicity
149 reports (19.7%)
#3 Most Reported
Eyelid ptosis
149 reports (19.7%)
All ENFUVIRTIDE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Lipodystrophy acquired | 150 | 19.8% | 0 | 0 |
| Eyelid ptosis | 149 | 19.7% | 0 | 0 |
| Mitochondrial toxicity | 149 | 19.7% | 1 | 1 |
| Diplopia | 147 | 19.4% | 0 | 0 |
| Anxiety | 89 | 11.7% | 8 | 83 |
| Psychotic disorder | 85 | 11.2% | 8 | 82 |
| Depression suicidal | 82 | 10.8% | 8 | 82 |
| Depressive symptom | 82 | 10.8% | 8 | 82 |
| Psychiatric decompensation | 82 | 10.8% | 8 | 82 |
| Psychomotor skills impaired | 82 | 10.8% | 8 | 82 |
| Suicidal ideation | 82 | 10.8% | 8 | 82 |
| Tearfulness | 82 | 10.8% | 8 | 82 |
| Paranoia | 81 | 10.7% | 8 | 81 |
| Dysphagia | 80 | 10.6% | 0 | 0 |
| Progressive external ophthalmoplegia | 74 | 9.8% | 0 | 0 |
| Foetal exposure during pregnancy | 64 | 8.4% | 9 | 0 |
| Injection site reaction | 60 | 7.9% | 0 | 0 |
| Ophthalmoplegia | 52 | 6.9% | 0 | 0 |
| Product use in unapproved indication | 45 | 5.9% | 6 | 44 |
| Blood lactic acid increased | 40 | 5.3% | 0 | 0 |
Who Reports ENFUVIRTIDE Side Effects? Age & Gender Data
Gender: 18.8% female, 81.2% male. Average age: 48.4 years. Most reports from: CA. View detailed demographics →
Is ENFUVIRTIDE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 3 | 0 | 0 |
| 2002 | 3 | 0 | 1 |
| 2003 | 3 | 1 | 0 |
| 2004 | 4 | 0 | 1 |
| 2005 | 11 | 0 | 5 |
| 2006 | 12 | 1 | 1 |
| 2007 | 4 | 1 | 4 |
| 2008 | 14 | 0 | 2 |
| 2009 | 12 | 0 | 1 |
| 2010 | 9 | 0 | 0 |
| 2011 | 17 | 0 | 0 |
| 2012 | 2 | 0 | 0 |
| 2013 | 5 | 1 | 1 |
| 2014 | 7 | 1 | 1 |
| 2015 | 5 | 0 | 1 |
| 2016 | 4 | 0 | 1 |
| 2017 | 7 | 0 | 4 |
| 2018 | 8 | 0 | 4 |
| 2019 | 4 | 0 | 2 |
| 2020 | 1 | 0 | 0 |
| 2021 | 5 | 2 | 3 |
| 2022 | 9 | 0 | 0 |
| 2023 | 17 | 0 | 0 |
| 2024 | 8 | 0 | 8 |
What Is ENFUVIRTIDE Used For?
| Indication | Reports |
|---|---|
| Hiv infection | 518 |
| Product used for unknown indication | 163 |
| Hiv test positive | 28 |
| Antiretroviral therapy | 11 |
| Maternal exposure timing unspecified | 11 |
| Acquired immunodeficiency syndrome | 10 |
| Antiviral treatment | 7 |
ENFUVIRTIDE vs Alternatives: Which Is Safer?
ENFUVIRTIDE vs ENOXAPARIN
ENFUVIRTIDE vs ENOXAPARIN - WINTHROP
ENFUVIRTIDE vs ENSIFENTRINE
ENFUVIRTIDE vs ENTACAPONE
ENFUVIRTIDE vs ENTECAVIR
ENFUVIRTIDE vs ENTINOSTAT
ENFUVIRTIDE vs ENTRECTINIB
ENFUVIRTIDE vs ENZALUTAMIDE
ENFUVIRTIDE vs EPCORITAMAB
ENFUVIRTIDE vs EPCORITAMAB-BYSP
Official FDA Label for ENFUVIRTIDE
Official prescribing information from the FDA-approved drug label.